Storia in 4 fonti

A turning point for pancreatic cancer patients

Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

fiercepharma.com2 g fa

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival…

Leggi questa versione → originale

statnews.com2 g fa

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Akeso and Summit Therapeutics' ivonescimab reduced the risk of death by 34% in squamous non-small cell lung cancer patients versus standard treatment, in a Phase III trial published in The Lancet. For biotech and pharma-adjacent tech buyers, the result validates dual-mechanism oncology biologics and strengthens Summit's pipeline valuation ahead of potential ex-China regulatory filings.

Timeline cronologica

sabato 30 maggio 2026·statnews.com
BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
sabato 30 maggio 2026·statnews.com
BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.

A turning point for pancreatic cancer patients

Confronto fonti

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Timeline cronologica

BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA

BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA

ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma

ASCO: Revolution Medicines confident in RAS leadership as rivals square up

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

ASCO: Revolution Medicines confident in RAS leadership as rivals square up

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

A standing ovation for RevMed, and caution for Akeso

A turning point for pancreatic cancer patients

Pharmalittle: We're reading about pancreatic and lung cancer drugs, China biotech growth, and more

ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma